Acrivon Therapeutics, Inc. Research and Development Expense
Acrivon Therapeutics, Inc. (ACRV) reported Research and Development Expense of $13.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Acrivon Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $13.84M, a 14.45% decline year-over-year.
- Acrivon Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $15.17M, a 1.61% decline year-over-year.
- Acrivon Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $14.75M, a 20.85% decline year-over-year.
- Acrivon Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $13.65M, a 27.65% decline year-over-year.
- Acrivon Therapeutics, Inc. research and development expense for fiscal 2025 was $59.99M, a 6.25% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. research and development expense for fiscal 2024 was $63.99M, a 39.04% increase from fiscal 2023.
- Acrivon Therapeutics, Inc. research and development expense for fiscal 2023 was $46.02M, a 92.18% increase from fiscal 2022.
- Acrivon Therapeutics, Inc. research and development expense for fiscal 2022 was $23.95M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.84M 10-Q · filed 2026-08-12 | $29.01M 10-Q · filed 2026-08-12 | $43.76M derived: sum of 3 quarters · filed 2026-08-12 | $57.40M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $15.17M 10-Q · filed 2026-05-13 | $29.91M derived: sum of 2 quarters · filed 2026-05-13 | $43.56M derived: sum of 3 quarters · filed 2026-05-13 | $59.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $14.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $28.39M derived: sum of 2 quarters · filed 2026-03-19 | $44.58M derived: sum of 3 quarters · filed 2026-08-12 | $59.99M 10-K · filed 2026-03-19 |
| 2025-09-30 | $13.65M 10-Q · filed 2025-11-13 | $29.83M derived: sum of 2 quarters · filed 2026-08-12 | $45.24M 10-Q · filed 2025-11-13 | $63.87M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $16.18M 10-Q · filed 2026-08-12 | $31.60M 10-Q · filed 2026-08-12 | $50.23M derived: sum of 3 quarters · filed 2026-08-12 | $69.09M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $15.41M 10-Q · filed 2026-05-13 | $34.04M derived: sum of 2 quarters · filed 2026-05-13 | $52.91M derived: sum of 3 quarters · filed 2026-05-13 | $67.93M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $18.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $37.49M derived: sum of 2 quarters · filed 2026-03-19 | $52.52M derived: sum of 3 quarters · filed 2026-03-19 | $63.99M 10-K · filed 2026-03-19 |
| 2024-09-30 | $18.86M 10-Q · filed 2025-11-13 | $33.89M derived: sum of 2 quarters · filed 2025-11-13 | $45.36M 10-Q · filed 2025-11-13 | $60.84M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $15.03M 10-Q · filed 2025-08-13 | $26.50M 10-Q · filed 2025-08-13 | $41.98M derived: sum of 3 quarters · filed 2025-08-13 | $52.24M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $11.47M 10-Q · filed 2025-05-14 | $26.95M derived: sum of 2 quarters · filed 2025-05-14 | $37.22M derived: sum of 3 quarters · filed 2025-05-14 | $47.74M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $15.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $25.75M derived: sum of 2 quarters · filed 2025-03-27 | $36.27M derived: sum of 3 quarters · filed 2025-03-27 | $46.02M 10-K · filed 2025-03-27 |
| 2023-09-30 | $10.27M 10-Q · filed 2024-11-13 | $20.79M derived: sum of 2 quarters · filed 2024-11-13 | $30.55M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $10.52M 10-Q · filed 2024-08-13 | $20.28M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $9.76M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $23.95M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |